3 Pharma Stocks With Upcoming Catalysts

Before you go, we thought you'd like these...
Before you go close icon

For investors in the biopharma arena, it's absolutely critical to understand the inherent risks of certain kinds of stocks. Whether you're looking to invest in developmental-stage companies with no revenue, or targeting profitable players with significant revenue concentrations, it's important to understand the catalysts that could lead to additional volatility.

Next week, Regeneron and Sucampo Pharmaceuticals are awaiting FDA approval decisions on new indications for their flagship products: Eylea and Amitiza, respectively. Synta, on the other hand, is expected to outline plans for its phase 3 trials of Ganetespib later this year. In the following video, Fool.com health care bureau chief Brenton Flynn helps to put these news items in the right perspective for investors.

Of course, keeping the right perspective when investing is a key to builiding long-term wealth and retiring well. In our exclusive special report titled "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you, as well as some winning wealth-building strategies. Click here to claim a free copy now.


The article 3 Pharma Stocks With Upcoming Catalysts originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners